Tru Niagen Review 2026: Best NR on the Market, but Is NR Still the Best NAD+ Strategy?

What Is Tru Niagen? Brand and Ingredient Background

Tru Niagen is a dietary supplement containing nicotinamide riboside chloride (NR), manufactured by ChromaDex (now Niagen Bioscience), a publicly traded company founded in 1999. NR is a form of vitamin B3 that the body converts to NAD+ (nicotinamide adenine dinucleotide), a coenzyme essential for cellular energy production, DNA repair, and hundreds of metabolic reactions.

ChromaDex licensed the Niagen NR molecule in 2012 and brought it to market as Tru Niagen. The company holds extensive patents on nicotinamide riboside production, which has historically limited competition and kept prices higher than NMN alternatives. ChromaDex also supplies its Niagen raw material to other brands, including Life Extension's NAD+ Cell Regenerator, which uses the same ingredient at the same 300 mg dose.

The product line includes several tiers: Tru Niagen 300 mg ($47–$49/month, standard dose), Tru Niagen Pro 500 mg ($65/month, higher dose per capsule), and Tru Niagen Pro 1000 mg ($116/month, the clinical trial dose). Stick packs for travel are also available at $58/month. All use the same Niagen NR chloride with minimal inactive ingredients (microcrystalline cellulose and a vegetarian capsule shell).

The Tru Niagen product line has evolved significantly since its initial launch. The original 300 mg capsule remains the entry point, but ChromaDex has expanded into higher-dose formulations (Pro 500, Pro 1000), specialized variants (Tru Niagen Immune, Tru Niagen Beauty with 100 mg NR as a stacking dose), and a powder stick pack format for travel. The Pro 1000 mg product ($116/month, 2 capsules daily) matches the 1,000 mg/day dose used in the company's key clinical trials, which is a meaningful distinction, most users taking the standard 300 mg are below the dose used in the most rigorous published research.

ChromaDex is publicly traded (NASDAQ: CDXC), which means its financial performance, research pipeline, and competitive strategy are publicly reported. This transparency is unusual in the supplement industry, where most brands are privately held. It also means ChromaDex has investor pressure to defend its NR market position against the rapidly growing NMN category, context that is worth keeping in mind when evaluating ChromaDex-funded research comparing NR favorably to NMN.

In May 2026, the National Advertising Review Board recommended that ChromaDex modify or discontinue certain advertising claims for Tru Niagen, reflecting the regulatory reality that NAD+ supplement claims remain under scrutiny even for the most studied brand in the category. This does not affect the ingredient's safety or efficacy data, it is an advertising compliance issue.

Tru Niagen Ingredients: What Is in Each Capsule

Each Tru Niagen capsule contains exactly one active ingredient: 300 mg of Niagen (nicotinamide riboside chloride). The inactive ingredients are microcrystalline cellulose (filler), hypromellose (vegetarian capsule shell), and vegetable magnesium stearate (flow agent in the standard version: the Pro version omits it). That is the entire formula.

This radical simplicity is both Tru Niagen's greatest strength and its limitation. The strength: you know exactly what you are taking, at exactly what dose, with zero proprietary blend ambiguity. Every milligram is accounted for. The limitation: NR alone does not address the full NAD+ ecosystem. Some researchers argue that combining an NAD+ precursor with methylation support (TMG/betaine), sirtuin activators (resveratrol), or mitochondrial cofactors (CoQ10) provides combined benefits. Products like Wonderfeel Youngr and Omre NMN + Resveratrol take this combined approach; Tru Niagen deliberately does not.

ChromaDex's position is that a single, well-studied molecule at a verified dose is better than a multi-ingredient stack where each component may be underdosed. There is scientific logic to this argument. But it does mean that users who want a longevity stack need to buy additional supplements separately, adding cost on top of Tru Niagen's already premium pricing.

The Clinical Evidence for NR: What Niagen Trials Actually Found

Niagen NR has been studied in 40+ published clinical trials, more than any other NAD+ precursor. The key dose-response trial (Conze et al., 2019; PMID 31278280) showed NR at 100/300/1,000 mg/day raised whole blood NAD+ by 22%/51%/142% respectively within 2 weeks, with increases maintained through the 8-week study and no serious adverse effects. This is the strongest single piece of evidence supporting Tru Niagen as a product.

The 40+ trial count is genuinely impressive and gives NR the deepest safety dataset of any NAD+ precursor. Key findings across the research body include safe and well-tolerated dosing up to 2,000 mg/day in multiple populations, consistent NAD+ elevation across all tested doses, and no clinically significant adverse events in any published trial.

Specific trial findings worth noting for informed purchasing decisions:

The Martens et al. (2018; PMID 29599478) trial in healthy middle-aged and older adults (n=24, crossover design, 1,000 mg NR/day for 6 weeks) found that NR was well-tolerated, raised NAD+ metabolites in blood, and showed a trend toward reduced systolic blood pressure and aortic stiffness, but the study was too small and short to reach statistical significance for cardiovascular outcomes.

The Elhassan et al. (2019; PMID 31412242) trial in older men (n=12, 1,000 mg NR/day for 21 days) demonstrated that NR augmented the skeletal muscle NAD+ metabolome and induced anti-inflammatory gene expression signatures. This is one of the stronger mechanistic findings, showing NR does reach muscle tissue and changes gene expression, but the sample size was very small and no functional outcomes (strength, endurance) were measured.

The NADPARK trial (Brakedal et al., 2022; PMID 35235774) tested NR in Parkinson's disease patients (n=30, 1,000 mg/day for 30 days) and found increased brain NAD+ levels and changes in cerebral metabolism by MRI. This is the most clinically significant NR trial to date, suggesting NR may have neurological applications, but again, a small, short pilot study that needs replication.

However, the trials have important limitations that ChromaDex's marketing tends to understate. Most NR trials measured NAD+ levels as the primary endpoint: not clinical health outcomes like reduced cardiovascular events, improved cognitive function, or extended lifespan. Raising NAD+ is a biomarker change, not a health outcome. Multiple trials testing NR for specific clinical outcomes, insulin sensitivity in obese men (Dollerup et al., 2018; PMID 29992272), skeletal muscle mitochondrial function (Elhassan et al., 2019; PMID 31412242), showed NAD+ went up but clinical improvements were modest or non-significant.

This is the honest picture: NR reliably raises NAD+, NR is safe, and NR has more published data than any competitor. But "raises NAD+" has not yet been conclusively translated into "improves specific health outcomes" in rigorous clinical trials. This limitation applies equally to NMN and to NR. For a complete evidence review of both precursors, see our NMN vs NR comparison.

Why NAD+ Matters: The Science Behind the Supplement Category

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell, required for over 500 enzymatic reactions including energy metabolism, DNA repair, and sirtuin activation. Human NAD+ levels decline by approximately 50% between ages 40 and 60 ( Massudi et al., 2012; PMID 22848760), and this decline is increasingly recognized as a contributing factor (not just a bystander) in aging-related metabolic dysfunction.

The scientific interest in NAD+ supplementation stems from a straightforward observation: as NAD+ levels drop with age, the cellular processes that depend on it become less efficient. Mitochondria produce less ATP (cellular energy), DNA repair mechanisms slow down, sirtuins (a family of longevity-associated enzymes) lose activity, and inflammatory signaling increases. This cascade is not theoretical, it is measurable in blood samples and tissue biopsies from aging humans.

The question Tru Niagen and every other NAD+ supplement attempts to answer is whether replenishing NAD+ through oral supplementation reverses or slows any of these age-related changes. The animal data is compelling: NR and NMN both extend healthspan (time spent in good health) in mice and improve metabolic markers across dozens of preclinical studies. The human data is promising but incomplete: NAD+ levels reliably go up, but downstream clinical benefits (reduced cardiovascular disease, improved cognitive function, extended lifespan) have not yet been confirmed in large, long-term trials.

This gap between "raises NAD+" and "improves health outcomes" is the central uncertainty of the entire NAD+ supplement category: not a specific weakness of Tru Niagen. It applies equally to every NR and NMN product on the market. What differentiates products is not whether they raise NAD+ (most do), but at what dose, at what cost, with what safety data, and with what level of manufacturing quality assurance. For a complete overview of NAD+ biology and supplementation strategies, see our What Is NAD+? guide and NAD+ decline after 40.

NR vs NMN: The Precursor Debate in 2026

The first direct human comparison trial found NR and NMN produce roughly equivalent NAD+ elevation when taken orally at comparable doses. A 2026 systematic review confirmed that no head-to-head RCT has compared NMN and NR for metabolic endpoints, and the available evidence is "structurally insufficient" for reliable indirect comparison. In practical terms: both work for raising NAD+, neither has proven superiority for health outcomes, and NMN costs significantly less per milligram.

This is the central question for anyone considering Tru Niagen in 2026: if NMN does the same thing for less money, why pay more for NR?

ChromaDex argues that NR has more clinical data, which is true, and that NR is more efficiently converted to NAD+ because NMN must first be converted to NR before crossing cell membranes, which is contested. A 2023 ChromaDex-funded preclinical study found that NMN is "primarily converted to nicotinamide and NR before being utilized for NAD+ synthesis." However, other researchers have identified a direct NMN transporter (Slc12a8) in certain tissues, and the relative contribution of direct versus indirect NMN uptake in humans remains an active area of investigation.

What the human data shows, stripped of corporate advocacy from either side:

The competitive landscape has shifted significantly since NMN's FDA status was resolved in September 2025. Before that, NMN occupied legal gray area in the US, which gave NR a regulatory advantage. With NMN now clearly classified as a dietary supplement, and with NMN's clinical trial pipeline expanding rapidly, the NR-exclusive value proposition has narrowed to two things: a deeper clinical safety record and the USP monograph. Both are real advantages, but whether they justify paying 2-3× more per milligram is a personal calculation. For the complete precursor comparison, see our NMN vs NR evidence guide.

Tru Niagen Side Effects and Safety

NR at doses up to 2,000 mg/day has shown no serious adverse events in published clinical trials. The most common reported side effects are mild GI discomfort (nausea, bloating), headache, and occasional flushing, all at low incidence rates. This is the best safety record of any NAD+ supplement, supported by the largest clinical trial dataset in the category.

ChromaDex's dose-response trial (Conze et al., 2019) specifically evaluated safety across 100 mg, 300 mg, and 1,000 mg daily doses over 8 weeks. No dose-related safety signals emerged. Blood chemistry, liver enzymes, kidney function, and hematological markers remained within normal ranges at all dose levels. This is reassuring and genuinely differentiates NR from less-studied NAD+ precursors.

It is worth comparing this safety profile to NMN's. NMN has been studied in 20+ published human trials at doses up to 1,250 mg/day with a similarly clean safety record, no serious adverse events, mild GI complaints as the most common report, and normal blood chemistry across dose ranges. The safety gap between NR and NMN is real (40+ vs 20+ trials) but narrowing with each new NMN publication. For most people, both precursors are well-tolerated, and neither has raised safety concerns that would favor one over the other at recommended doses. For the complete safety comparison, see our NMN side effects guide (12+ human trials reviewed).

One theoretical concern with any NAD+ precursor is methylation demand. Converting NR (or NMN) to NAD+ consumes methyl groups, which could theoretically deplete methylation capacity in people with MTHFR variants or low B12/folate status. Some practitioners recommend pairing NAD+ precursors with TMG (trimethylglycine) or B-complex supplements to maintain methylation balance. Tru Niagen does not include methylation support, so users may want to consider this addition. For complete side effect data across all NMN and NR products, see our NMN side effects guide.

Tru Niagen Pricing: Is It Worth the Premium?

At $1.58/day for 300 mg (standard) to $3.87/day for 1,000 mg (Pro), Tru Niagen is the most expensive NAD+ precursor supplement per milligram. The premium pays for the Niagen patent, ChromaDex's extensive clinical trial investment, the 2026 USP monograph, and the deepest safety dataset of any NAD+ supplement. Whether that premium is justified depends on how much you value regulatory credibility versus raw cost-effectiveness.

The annual cost comparison makes the decision stark:

Product	Daily Dose	Cost/Day	Annual Cost	NAD+ Precursor
Tru Niagen 300mg	300 mg NR	$1.58	$577	NR (Niagen patent)
Tru Niagen Pro 1000mg	1,000 mg NR	$3.87	$1,413	NR (Niagen patent)
Thorne NiaCel 400	415 mg NR	$1.23	$449	NR (non-Niagen)
Life Extension NAD+ Cell Regenerator	300 mg NR	$0.97	$354	NR (Niagen license)
NMN 500mg (market average)	500 mg NMN	$0.80–$1.33	$292–$486	NMN

If you are committed to NR specifically, because you trust the deeper clinical dataset, because your healthcare provider recommends it, or because you value the USP monograph, Life Extension's NAD+ Cell Regenerator uses the same Niagen raw material at a lower price point. For a broader view of NAD+ supplementation options, see our NAD+ supplement guide and NMN supplement guide.

Who Should Buy Tru Niagen

Tru Niagen is the right choice for people who specifically want NR (not NMN), who value the deepest clinical safety dataset, who prioritize the USP monograph and Niagen patent credibility, or whose healthcare provider specifically recommends NR. It is not the right choice for cost-conscious buyers, for people who want a multi-ingredient longevity stack, or for those who find the NMN clinical evidence sufficient.

Buy Tru Niagen if:

• Your healthcare provider specifically recommends NR or Tru Niagen by name
• You value having the largest clinical trial safety dataset supporting your supplement
• You prefer the regulatory certainty of a USP monograph (established 2026 for NR chloride)
• You want a single-ingredient product with zero proprietary blend risk: what you see is what you get
• You are willing to pay a premium for the Niagen brand and ChromaDex's research investment

Consider NMN instead if:

• Budget matters, NMN delivers equivalent NAD+ elevation at roughly half the cost per milligram
• You want a higher dose without proportionally higher cost (1,000 mg NMN costs $1.00–$1.50/day vs $3.87 for Tru Niagen Pro)
• You find the NMN clinical evidence (20+ published human trials) sufficient for your risk tolerance
• You want to combine your NAD+ precursor with resveratrol, TMG, or other longevity compounds, multi-ingredient NMN products exist; NR options are more limited
• The September 2025 FDA reinstatement of NMN as a dietary supplement addresses your regulatory concern

Consider Life Extension NAD+ Cell Regenerator if:

• You want the same Niagen NR molecule as Tru Niagen at a 30-40% lower price point
• You are already a Life Extension customer and purchase through their subscription program
• You want NR specifically but find Tru Niagen's pricing unjustifiable given that the raw material is identical

Skip NAD+ supplements entirely if:

• You are under 30, NAD+ decline is minimal before age 30-35, and the cost-benefit ratio is poor
• You have not addressed foundational health first, sleep, exercise, diet, and basic vitamin D/magnesium levels have more evidence for improving health outcomes than any NAD+ precursor
• You are looking for a supplement to treat a specific medical condition, NAD+ precursors are not approved treatments for any disease, and anyone claiming otherwise is misrepresenting the evidence

For a detailed comparison of specific NMN products with independently verified purity and published COAs, see our NMN supplement guide. For the complete NR vs NMN precursor comparison, see NMN vs NR: Which NAD+ Precursor Is Better?

NR Delivery Forms: Capsules, Powder, and Stick Packs

Tru Niagen is available in standard capsules (300 mg, 500 mg, and 1,000 mg per serving) and unflavored powder stick packs (300 mg). NR is generally stable in capsule form and does not require special storage conditions, unlike some NMN formulations that recommend refrigeration. The capsule format uses delayed-release technology to protect the NR molecule through stomach acid, though the clinical significance of this delivery enhancement over standard capsules is not established in published comparisons.

The stick pack format ($1.93/day for 300 mg) costs more per serving than the capsule ($1.58/day) but offers portability for travel. It mixes into water or any cold beverage. ChromaDex advises against mixing with hot beverages, as heat may degrade nicotinamide riboside: the same precaution that applies to NMN powder. For a broader comparison of NAD+ precursor delivery formats, including sublingual NMN, liposomal NR, and IV NAD+, see our NMN delivery format comparison and NAD+ supplement guide.

How Tru Niagen Compares to Other NR Products

If you are set on NR specifically, three alternatives are worth considering: Life Extension NAD+ Cell Regenerator (same Niagen ingredient, lower price), Thorne NiaCel 400 (non-Niagen NR, NSF Certified for Sport, lowest cost per mg), and Pure Encapsulations NR Longevity (NR + resveratrol + quercetin stack). Each trades off a different aspect against Tru Niagen's brand prestige.

Life Extension NAD+ Cell Regenerator contains 300 mg of the same Niagen NR at approximately $0.97/day, roughly 40% less than Tru Niagen for the identical active ingredient. Life Extension licenses Niagen from ChromaDex, so the raw material is the same. The price difference is pure brand margin. If you trust Niagen as an ingredient but do not need the Tru Niagen brand name, this is the most straightforward cost reduction. We cover Life Extension's full NAD+ line in a separate review.

Thorne NiaCel 400 uses a non-Niagen form of NR (nicotinamide riboside hydrogen malate, 415 mg/serving) at $1.23/day, lower cost per milligram than Tru Niagen and with NSF Certified for Sport status. Thorne and ChromaDex were previously in patent litigation (resolved 2021-2024), and Thorne's NR formulation is distinct from Niagen. For athletes who specifically need NSF Certified for Sport, NiaCel is currently the only NR option with that certification.

Pure Encapsulations NR Longevity combines 300 mg NR with resveratrol and quercetin in a single product. This addresses the "NR alone isn't a complete longevity stack" limitation but at higher overall cost and with less clinical data supporting the specific combination. For the stacking approach to longevity supplementation, see our NMN and resveratrol guide.

The Decision Framework: How to Choose Your NAD+ Supplement

Rather than debating NR vs NMN in abstract, a practical decision framework considers five factors: your budget, your tolerance for regulatory uncertainty, whether you want a single ingredient or a stack, whether you need third-party sport certification, and whether your healthcare provider has a specific recommendation. Most people making a new NAD+ purchase in 2026 will find that NMN at 250-500 mg/day offers the best balance of evidence, cost, and practical value.

Budget-first buyers ($15-$30/month): NMN at 250-500 mg/day from a third-party-tested brand with published COAs. At this price point, you get a clinically studied dose of an NAD+ precursor that produces equivalent NAD+ elevation to NR, with full dose transparency. This is the approach that gives you the most NAD+ per dollar. See our NMN supplement guide for specific product recommendations at this price tier.

Evidence-first buyers ($45-$65/month): Tru Niagen 300 mg or Life Extension NAD+ Cell Regenerator if you want the deepest safety dataset and USP monograph backing. NR's 40+ trial count is a genuine differentiator for people who weight regulatory maturity above cost. At this budget, you could also choose NMN at 500-1,000 mg/day for a higher dose at similar total cost.

Stack builders ($50-$100/month): An NMN product combined with resveratrol (for sirtuin activation), TMG (for methylation support), and vitamin D3+K2 (for foundational health). Products like Wonderfeel Youngr bundle NMN with complementary compounds in a single product. Alternatively, you can build a custom stack by sourcing each ingredient separately, often cheaper and with full dose control. See our NMN and resveratrol guide for the stacking evidence.

Athletes needing NSF Certified for Sport: Thorne NiaCel 400 is currently the only NR product with NSF Certified for Sport status. This is a narrow but important use case for competitive athletes subject to anti-doping testing. Tru Niagen does not carry NSF Certified for Sport.

Healthcare-provider-directed users: If your doctor or longevity practitioner specifically recommends NR or Tru Niagen, follow their guidance. They may have reasons related to your specific health profile, medication interactions, or clinical trial eligibility that override general cost-effectiveness calculations.

The NAD+ Precursor Landscape in 2026: Where Things Stand

The NAD+ supplement market is evolving rapidly. NR held a near-monopoly on the space from 2013 to 2023, largely due to ChromaDex's patents and NMN's regulatory uncertainty. With NMN's FDA reinstatement, the competitive landscape has shifted decisively: NMN offers equivalent NAD+ elevation at lower cost, with a rapidly growing clinical trial base. NR retains advantages in safety data depth and regulatory maturity. For most consumers making a new purchasing decision in 2026, NMN provides better value.

The scientific reality that both camps would prefer to obscure is this: neither NR nor NMN has been proven to meaningfully extend human lifespan, reduce cardiovascular disease, prevent cognitive decline, or treat any specific medical condition. Both reliably raise NAD+ levels in blood and tissue. Whether that translates to the longevity benefits observed in animal models remains an open question that larger, longer human trials will eventually answer.

Until those trials report, the choice between NR and NMN is a bet on which precursor will prove more clinically relevant, or a practical decision based on cost, safety data, and personal preference. Tru Niagen is the best-credentialed NR product on the market. Whether NR is the best NAD+ strategy is a separate and more important question.

For a complete map of NAD+ supplementation options, NR, NMN, NAD+ direct, IV therapy, and lifestyle interventions, see our NAD+ supplements guide and NAD+ decline after 40.

Frequently Asked Questions

Is Tru Niagen the same as NMN?

No. Tru Niagen contains nicotinamide riboside (NR), not nicotinamide mononucleotide (NMN). Both are NAD+ precursors from the vitamin B3 family, but they are different molecules. NR is the smaller molecule; NMN is NR with a phosphate group attached. In the metabolic pathway, NR is converted to NMN, which is then converted to NAD+. See our NMN vs NR comparison for the complete evidence breakdown.

How long does Tru Niagen take to raise NAD+?

Clinical trial data shows detectable NAD+ elevation within hours of a single dose of NR, with sustained increases measurable at 2 weeks and peaking around 8 weeks of daily use. The Conze et al. Dose-response trial found that 300 mg/day raised whole blood NAD+ by 51% within 2 weeks (maintained through 8 weeks).

Can I take Tru Niagen with NMN?

Some longevity practitioners recommend combining NR and NMN for "complementary pathway coverage," but no published clinical trial has evaluated this combination in humans. Both converge on the same NAD+ synthesis pathway, so the additive benefit is theoretical. If you decide to stack, monitor for over-methylation symptoms and consider adding TMG. See our NAD+ supplement guide for stacking considerations.

Why is Tru Niagen so expensive?

Three reasons: ChromaDex's Niagen patent (which limits generic NR competition), the company's investment in 40+ clinical trials, and the 2026 USP monograph development. Whether this justifies the 2-3× price premium over NMN depends on how much you value regulatory maturity and safety data depth versus cost-effectiveness.

Is Life Extension NAD+ Cell Regenerator the same as Tru Niagen?

The active ingredient is the same, both use ChromaDex's Niagen NR at 300 mg. Life Extension licenses Niagen from ChromaDex. The difference is brand and price: Life Extension typically costs 30-40% less than Tru Niagen for the identical active ingredient.

Does Tru Niagen have side effects?

In clinical trials at doses up to 2,000 mg/day, serious adverse events were not reported. Mild GI discomfort, headache, and occasional flushing occur at low rates. NR is generally one of the best-tolerated supplements in the NAD+ category, with the deepest published safety dataset.

Should I take 300 mg or 1,000 mg of NR?

The 300 mg dose raises NAD+ by approximately 51% within two weeks and costs $1.58/day. The 1,000 mg dose (used in most functional clinical trials) raises NAD+ by approximately 142% and costs $3.87/day. Whether the additional NAD+ elevation translates to additional clinical benefit is unknown, no trial has compared health outcomes between these dose levels. Many users start at 300 mg and consider escalating only if they want maximum NAD+ elevation and are comfortable with the cost. For dosing guidance across NAD+ precursors, see our NMN dosage guide and NAD+ supplement guide.

What happened with the NARB advertising ruling in 2026?

The Tru Niagen product line has evolved significantly since its initial launch. The original 300 mg capsule remains the entry point, but ChromaDex has expanded into higher-dose formulations (Pro 500, Pro 1000), specialized variants (Tru Niagen Immune, Tru Niagen Beauty with 100 mg NR as a stacking dose), and a powder stick pack format for travel. The Pro 1000 mg product ($116/month, 2 capsules daily) matches the 1,000 mg/day dose used in the company's key clinical trials, which is a meaningful distinction, most users taking the standard 300 mg are below the dose used in the most rigorous published research.

ChromaDex is publicly traded (NASDAQ: CDXC), which means its financial performance, research pipeline, and competitive strategy are publicly reported. This transparency is unusual in the supplement industry, where most brands are privately held. It also means ChromaDex has investor pressure to defend its NR market position against the rapidly growing NMN category, context that is worth keeping in mind when evaluating ChromaDex-funded research comparing NR favorably to NMN.

In May 2026, the National Advertising Review Board recommended that ChromaDex modify or discontinue certain marketing claims for Tru Niagen. This is an advertising compliance matter, it does not affect the ingredient's safety data, clinical trial results, or the USP monograph. It reflects the broader regulatory environment where supplement companies face increasing scrutiny over health-related claims.

Is NR or NMN better for anti-aging?

Neither has been proven to extend human lifespan or reverse aging in published clinical trials. Both raise NAD+ levels comparably in human studies. NR has more published safety data; NMN has emerging evidence for insulin sensitivity in pre-diabetic women. For most people making a new decision in 2026, NMN provides equivalent NAD+ elevation at lower cost. The choice is between NR's regulatory maturity and NMN's price advantage. See our complete NMN vs NR analysis.